Antisecretory factor (AF), also named S5a, is a 43 kDa ubiquitously expressed protein originally identified through its capacity to inhibit intestinal hypersecretion(Reference Johansson, Lonnroth and Lange1). Further studies have shown that AF is also a potent anti-inflammatory agent(Reference Davidson and Hickey2–Reference Eriksson, Shafazand and Jennische6). In the plasma of healthy individuals, the major part of AF is present in an inactive form(Reference Johansson, Lonnroth and Jonson7). AF is activated through intestinal exposure to bacterial toxins or through the intake of specific food components, e.g. in the form of specially processed cereals (SPC)(Reference Johansson, Lonnroth and Jonson7–Reference Hanner, Rask-Andersen and Lange9). Clinical studies have shown that a diet-induced increase in AF activity is beneficial for a number of diseases in which inflammation and/or secretory disturbances are parts of the pathophysiology(Reference Eriksson, Shafazand and Jennische6, Reference Bjorck, Bosaeus and Ek8, Reference Hanner, Rask-Andersen and Lange9).
The mechanisms through which SPC activate AF are currently unknown, although exposure of the intestinal mucosa to SPC, in certain aspects, may be assumed to mimic that of intestinal exposure to bacterial toxins, i.e. by inducing an inflammatory response. Such a response could be a first step in the activation process. In a previous study, proteomics was used to study the differences in protein expression in the livers of rats fed an SPC feed and rats fed a standard feed(Reference Johansson, Lange and Jennische10). A selective increase in the expression of glutathione-S-transferase μ in the livers of rats fed the SPC feed was observed. Glutathione-S-transferase μ does not appear to be involved in AF activation, and the increased expression is probably an unrelated effect of the SPC feed.
In a recent study, in which rats were exposed to blast injury to the head, it was found that pre-treatment with a feed containing SPC prevented the animals from developing high intracranial pressure (ICP), otherwise induced by this type of injury(Reference Saljo, Bolouri and Mayorga11). However, only one concentration of SPC was used and no analyses of AF activity were made. It was unclear whether the effect on ICP was due to AF or if other effects of the SPC feed also contributed.
The aim of the present study was to investigate the time and dose relationships between SPC intake and plasma AF activity and to investigate whether the level of AF activity could be correlated with a biological effect. Rats were fed with different concentrations of SPC for 2 or 4 weeks and the AF activity in plasma was analysed. Furthermore, analyses of the complement factors C3c and factor H were carried out in order to investigate if the SPC feed affected the complement system. A number of animals from each feed group were subjected to a closed head injury, known to induce a high ICP. ICP was measured at 2 d after the insult, and the obtained values were correlated with the percentage of SPC in the feed.
Material and methods
Animals
Male Sprague–Dawley rats, having a body weight of 180 (sem 20) g (Harlan Laboratories), were used. After arrival, the rats were given a week for general adaptation, with free access to pelleted feed and water. The temperature and air ventilation in the animal quarters were monitored and controlled, according to standard procedures. The number of animals in each experimental group is presented in the figures and figure legends.
The test protocol was approved by the Regional Animal Experiments Ethical Committee and performed in accordance with guidelines for animal experiments (EC Directive 86/609/EEC).
Feed
Endogenous formation of the protein AF was stimulated in adult rats by mixing 5, 10 or 15 % SPC (SPC Flakes®; Lantmännen AS-Faktor AB) to standard rat feed (Lab For R36; Lantmännen). The feed, prepared with SPC and R36, was mixed, pelleted and processed in the same way as the R36 feed, therefore, not differing in appearance. Each batch was coded and quality controlled by the Lantmännen standard procedure. The composition of the feeds is given in the work by Johansson et al. (Reference Johansson, Lange and Jennische10).
Chemicals
Isoflurane was purchased from Baxter Medical AB; all other chemicals were obtained from Sigma-Aldrich. Monoclonal antibodies against the AF protein were produced and characterised in-house(Reference Johansson, Lonnroth and Jonson7). The rabbit anti-C3c polyclonal antibody was purchased from Dako and the rabbit anti-factor H polyclonal antibody from Santa Cruz Biotechnology (SDS Biosciences). The alkaline phosphatase-conjugated goat anti-mouse IgM antibody and goat anti-rabbit IgG antibody were purchased from Jackson ImmunoResearch Europe Limited.
Feed-induced stimulation of antisecretory factor formation
A total of ten groups of rats were fed with the control R36 feed or with different concentrations of SPC mixed with R36: two groups were fed R36 for 2 weeks; two groups, 5 % SPC for 2 weeks; two groups, 10 % SPC for 2 weeks; and two groups, 15 % SPC for 2 weeks. Two groups were fed 5 % SPC for 4 weeks. One group of animals from each feeding schedule was used for ELISA analyses. One group from each feeding schedule was subjected to a head injury and subsequent ICP measurements.
Determination of plasma antisecretory factor activity
The AF activity in purified plasma was determined by means of an ELISA method developed in-house, as previously reported(Reference Johansson, Lonnroth and Jonson7). The AF activity in the purified samples was determined, using the monoclonal antibody 3H8(Reference Johansson, Lonnroth and Jonson7) as the detecting antibody. The bound enzyme in the assay was revealed by absorbance at 405 nm. Data are presented as means with their standard errors.
ELISA determination of complement factors C3c and factor H
The levels of C3c and factor H in the affinity-purified rat plasma samples were determined by an ELISA method, using rabbit anti-C3c or anti-factor H polyclonal antibody as the detecting antibody. A second antibody of goat anti-rabbit IgG-alkaline phosphatase conjugate was then applied, followed by absorbance readings at 405 nm, to reveal the bound enzyme. Rabbit pre-immune serum was used as the background and the values were deducted to give net absorbances. Data are presented as means with their standard errors.
Surgical procedure and induction of a traumatic brain injury
A modification of the method described by Schneider et al. (Reference Schneider, Hennig and Lanksch12) was used. The operation procedure started by inhalation of isoflurane, after which the anaesthetised rat was positioned on the abdomen, on a heating pad, the head shaved and a midline incision made through the skin and fascia on the skull vault. The calvarium was freed of adherent tissue and a Cu rod (144 g) with a tip diameter of 4 mm, kept immersed in liquid N2, was then applied to the right parietal bone for 45 s. This freezing procedure induced a superficial injury to the underlying brain tissue. The midline of the cranium was avoided in order to not induce any damage to the superior sagittal sinus. The wound was then sutured, the rat received an analgesic and recovered from the anaesthesia. All animals survived the anaesthesia and the operation procedure, and none showed any signs of subsequent impairment. Body temperatures were monitored with a rectal probe (Panlab temp control unit HB 101/2; Harvard Apparatus) and blood pressures were measured by intermittent cuffing of tail vessels (LE 5002; Panlab).
Measurement of intracranial pressure
ICP was measured, under isoflurane anaesthesia, at 2 d after the traumatic brain injury, as previously described(Reference Jennische, Bergstrom and Johansson13). In short, two light emitting diode (LED) fibre optic pressure transducers (Samba Sensors AB) connected to a control unit (Samba 3200) and a computer were inserted into the right and left hemispheres of the brain through two small holes (diameter 1 mm). Two pressure transducers were used to check the accuracy of the measurements. A similar ICP recorded from both sides indicate that the system is functioning properly.
The diameter of the optic fibre was 0·25 mm and that of the sensor was 0·42 mm. The pressure sensors were factory calibrated and the accuracy of the readings checked prior to and after the experiments. The calibration procedure was performed by immersion of the sensors in water-filled glass cylinders of known dimensions. Additionally, during the experimental periods, the probes were calibrated intermittently against the ambient atmospheric pressure, using the software supplied by the manufacturer. Data are presented as means with their standard errors. The animals were killed after the registration period.
Statistics
Values are expressed as means with their standard errors. In order to stabilise variances, values were logarithm-transformed using the natural logarithm. For investigation of dosage–response relationships after 2 weeks of feeding, a variance analysis followed by Turkey's test for multiple comparisons were used. For each analysis performed (ICP, AF, C3c and factor H), paired comparisons were made between all groups fed the various percentages of SPC. A value of P less than 0·05 was considered to be statistically significant. For comparison of the two groups fed 5 % SPC for 2 and 4 weeks, respectively, Student's two-tailed t test for independent samples was used. A value of P less than 0·05 was considered to be statistically significant. SPSS software (version 18; SPSS) was used for statistical evaluation.
Results
Effects of 5, 10 and 15 % specially processed cereals on rat plasma antisecretory factor activity
In animals fed the various SPC concentrations for 2 weeks, the plasma levels of active AF increased with increasing percentage of SPC (Fig. 1). A significant increase was induced by the 10 and 15 % SPC feeds (P< 0·01 and P< 0·001, respectively), but not by the 5 % SPC feed. AF activity after 4 weeks of feeding with 5 % SPC was slightly higher than after a 2-week feeding period (P< 0·05).
Effects of 5, 10 and 15 % specially processed cereals on complement factors C3c and factor H
Complement factors C3c and factor H were used as biomarkers for immune/inflammatory activation after dietary intake of SPC(Reference Palarasah, Skjodt and Brandt14) (Fig. 2). C3c levels after 2 weeks of feeding with the various SPC concentrations did not significantly differ from that in animals fed the control feed for any of the SPC concentrations. However, extending the feed period with 5 % SPC to 4 weeks resulted in a significant increase in the C3c level compared with that obtained after 2 weeks (P< 0·001) (Fig. 2(a)).
The levels of factor H were significantly increased after intake of 10 % SPC for 2 weeks (P< 0·01) (Fig. 2(b)). The factor H level after 4 weeks of feeding with 5 % SPC was significantly higher than after 2 weeks of feeding with 5 % SPC (P< 0·001).
Effects of 5, 10 and 15 % specially processed cereals on intracranial pressure in normal rats and after brain injury
ICP values are shown in Fig. 3. ICP in uninjured rats fed with the control feed R36 was 6·2 (sem 0·2) mmHg in the left hemisphere and 6·3 (sem 0·2) mmHg in the right hemisphere. As the ICP difference between the right and left hemispheres was not significant in any of the groups of animals, the mean of the two pressures were used for the statistical calculations.
Brain injury resulted in an increased ICP at 2 d after the insult in all groups of animals (P< 0·001 v. uninjured controls). The highest levels were obtained in the group of rats fed the control R36 feed (22·9 (sem 1·6) and 25·4 (1·4) mmHg, in the right and left hemispheres, respectively). In all groups of animals treated with the various SPC feeds for 2 weeks before the injury, ICP was significantly lower than that in the group fed the control feed.
In the group fed with 5 % SPC for 2 weeks, ICP was significantly lower, compared with the group fed the control feed (P< 0·05), and a further decrease in ICP was seen in animals fed the 10 % SPC feed (P< 0·001, 5 % SPC v. 10 % SPC). Increasing the percentage of SPC in the feed to 15 % had no further effect on the measured ICP.
If the feeding period with 5 % SPC before the injury was extended to 4 weeks, ICP at 2 d after injury was significantly lower than in animals fed 5 % SPC for 2 weeks (P< 0·001).
Discussion
Induction of AF activity occurs as a response to intestinal exposure of bacterial toxins, e.g. cholera toxin(Reference Lange and Lonnroth15). The increased AF activity is part of the natural response to diarrhoeal diseases and contributes to the healing process. This naturally occurring activation of AF can be mimicked by the intake of specific feed components consisting of a mixture of sugars and amino acids(Reference Lonnroth and Lange16). Such a mixture is obtained in SPC, and intake of SPC is followed by increased AF activity in plasma(Reference Johansson, Lonnroth and Jonson7). In previous human studies, a standardised dose of SPC based on body weight was used(Reference Bjorck, Bosaeus and Ek8, Reference Hanner, Rask-Andersen and Lange9, Reference Hanner, Jennische and Lange17). We now show that induced AF levels are related to the percentage of SPC in the feed as well as to the period of intake.
The biological significance of an increased AF activity for brain function was demonstrated by evaluating the response to a closed head injury. Thus, rats fed SPC for at least 2 weeks prior to the injury were protected from the ensuing ICP increase in a dose- and time-dependent manner. The present finding of a graded response correlated with the SPC percentage in the feed indicate that AF is responsible for a major part of the prevention of ICP increase. However, other effects of SPC unrelated to AF activity cannot be excluded(Reference Johansson, Lange and Jennische10).
The exact activation steps for AF are unknown, although both modes of induction, i.e. exposure to bacterial toxins or intake of feed components, probably occur through similar pathways. In the present study, plasma levels of the complement factors were observed to increase in a time-dependent manner after intake of SPC. It appears that SPC, possibly as an early step in the activation process, induces an inflammatory reaction, which is reflected in the plasma levels. Cholera toxin, a potent activator of AF(Reference Lange and Lonnroth15, Reference Lonnroth and Lange16), induces only a mild inflammatory reaction(Reference Flach, Lange and Jennische18), although it may be sufficient for the activation process.
The mechanism of action for AF is unknown. Previous studies have shown that endogenously produced protein AF and exogenously administrated AF peptides have similar effects in several experimental systems(Reference Kim, Wasling and Xiao19). Taken together, the results of previous experimental and clinical studies indicate that the effects of AF are, to a large extent, exerted through inhibition or modulation of inflammation(Reference Davidson and Hickey2, Reference Davidson and Hickey3, Reference Eriksson, Shafazand and Jennische6, Reference Johansson, Jennische and Lange20, Reference Al-Olama, Wallgren and Andersson21). In a recent study, constitutive mRNA levels of AF were found to vary between mouse strains, and a higher amount of AF due to genetic background may contribute to resistance to brain injury by counteracting inflammation(Reference Graber, Harris and Hickey22). A possible sequence of events could be that intake of SPC induces a mild inflammatory reaction, which is accompanied by formation of active AF. When formed, active AF protein acts as an anti-inflammatory agent.
The injury model used in the present study results in a combined cytotoxic and vasogenic oedema(Reference Schneider, Hennig and Lanksch12), of which inflammation is probably a prominent feature(Reference Schmidt, Heyde and Ertel23, Reference Simard, Kent and Chen24). It is tempting to suggest that AF exerts its anti-inflammatory action by inhibiting release of pro-inflammatory cytokines from cell populations present in most tissues, e.g. mast cells(Reference Strbian, Kovanen and Karjalainen-Lindsberg25) or macrophages/microglia(Reference Knerlich, Schilling and Gorlach26). A further effect of traumatic brain injury, contributing to inflammation and brain oedema, is an increase in NO due to the expression of inducible NO synthase(Reference Cherian, Hlatky and Robertson27). Inhibitor of NOS, e.g. VAS203(Reference Terpolilli, Zweckberger and Trabold28), has been shown to decrease brain oedema and intracranial hypertension after experimental traumatic brain injury. The peak in inducible NO synthase induction occurs between 6 and 72 h after a brain injury(Reference Knerlich, Schilling and Gorlach26), which coincides with the time point at which the ICP measurements were made in the present study. Further studies are needed to investigate if inducible NO synthase/NO effects can be modified by AF.
The present results demonstrate that AF activity in plasma increases in a dose- and time-dependent manner after intake of SPC. The SPC-induced AF activation process involves an inflammatory reaction. The data also indicate a dose–response relationship between the level of active AF and its biological effects in vivo. If the present results are applicable also for human subjects, they allow for a more individualised AF treatment in future studies.
Acknowledgements
All authors were involved in the study design, analyses of data and preliminary writing of the manuscript. E. Johansson carried out the ELISA analyses. M. A.-O. performed the ICP measurements. H.-A. H. took the ICP measurements. S. L. designed and controlled the feeding experiments and collected the blood samples. E. Jennische took part in the animal experiments and wrote the final manuscript. H.-A. H. and S. L. acted as scientific advisors to Lantmännen AS-Faktor AB. E. Johansson, M. A. O. and E. Jennische declare no conflict of interest. The authors are grateful to Dr Svante Höjer, PhD, Samba Sensors AB, for advice and support and Ms I. Jonson, Ms M. Rosenkvist for technical support. Dr Leif Göransson prepared the SPC and the mixed feed. Dr Kjell Petterson (Akademistatistik – Gothenburg University) made the statistical calculations.
The present study was supported by grants from the Swedish Government (grant LUA/ALF no. 71570), the Sahlgrenska University Hospital (grant no. 83030), the Ministry of High Education UAE, Magnus Bergvall Foundation, W. and M. Lundgren Foundation, Frimurare-Barnhus direktionen, Göteborg Medical Society, AB Nectin and Lantmännen AS-Faktor AB.
SPC® is protected by patents and registered trademarks of Lantmänner AS-Faktor AB, Box 30 192, SE 104 25 Stockholm, Sweden (www.as-faktor.se).